CISTO Study at AUA 2025: Dr. John Gore on Surgery vs. Bladder-Sparing in High-Grade NMIBC
In this episode of OncoDaily Talks, host Dr. Chandler Park is joined by Dr. John Gore and Dr. Petros Grivas to discuss the landmark CISTO study, presented at AUA 2025, which evaluates treatment options and quality-of-life outcomes in BCG-unresponsive non–muscle-invasive bladder cancer.
Key Highlights:
Radical cystectomy remains a key option for select patients
CISTO enrolled 570 patients from 36 U.S. sites, including community settings
Primary endpoint: 12-month physical function—non-inferior in patients undergoing cystectomy
Cystectomy group showed better emotional well-being and financial outcomes
Launch of CISTO-2: evaluating new therapies with financial toxicity as a primary endpoint
Upcoming long-term 2- and 5-year data; inclusion of caregiver quality-of-life measures
Powered by collaboration with BCAN (Bladder Cancer Advocacy Network)
Gain insights into how CISTO is shaping real-world treatment decisions and supporting shared decision-making in bladder cancer care.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023